Enteryx reimbursement
This article was originally published in The Gray Sheet
Executive Summary
Results from Boston Scientific's ongoing U.S. and European gastrointestinal reflux disease treatment randomized placebo studies will be used to obtain private payor coverage. The 60-patient European study completed enrollment March 3, and enrollment for the 120-patient U.S. study is expected to conclude this summer. Both trials feature equal-sized treatment and placebo arms, with one-, three- and 12-month follow up. Enteryx recently received a CPT code for Medicare outpatient payment (1"The Gray Sheet" Nov. 24, 2003, In Brief)...